Decoding Technological Advances in Biomanufacturing

Decoding Technological Advances in Biomanufacturing

Growing Viral Vector Contract Development Manufacturing Landscape

RELEASE DATE
29-Jun-2020
REGION
Global
Deliverable Type
Technology Research
Research Code: D99B-01-00-00-00
SKU: HC03315-GL-TR_24558
AvailableYesPDF Download

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03315-GL-TR_24558

$4,950.00

$3,712.50save 25 %

DownloadLink
ENQUIRE NOW

Description

The rise in gene therapies over the last few years has created a huge opportunity for viral vector Contract Research Development Organization (CMO/CDMO) to fill the gap of high demand and shortage of viral vectors. As of January 2020, the US Food and Drug Administration FDA has approved four gene therapies and claims to have over 900 therapies in the pipeline. This creates a huge demand for viral vectors.

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

1.1 Key findings

1.2 Analysis Framework: Frost & Sullivan’s Core Value

1.3 Research Methodology

2.1 Advantages of Using Viral Vectors

2.2 Factors for Selection of Viral Vectors

2.3 Commonly used Viral Vectors

2.4 Suitable Scenario for Viral Vector Manufacturing

3.1Global Viral Vector Market

3.2 Challenges to Overcome

3.3 Increasing competition among viral vector CDMOs

3.4 Technology Adopted to Increase Production Rates

3.5 Mergers & Acquisitions

3.6 Research Collaborations

3.7 Long Term Collaborations

3.8 Recent Innovations at Viral Vector CDMOs

3.9 Digital Workflow Platforms

3.10 Recently Expanded Viral Vector BioManufacturing Units

3.11 Rising Trend of Expansion among Viral Vector CDMOs

3.12 Role of viral vector CDMO in COVID-19 scenario

3.13 Viral vector cdmos provide services for COVID-19 vaccine development

4.1 Innovation Radar of Viral Vector CDMOs

4.2 Summary of the Scoring Methodology

4.3 Advanced Bioscience Labs (ABL) Inc.

4.4 Batavia Bioscience

4.5 Biovian

4.6 CEVEC

4.7 Cobra Biologics

4.8 Oxford Genetics

4.9 Catalent

4.10 Molmed

4.11 Vigene

4.12 ProBiogen

4.13 Oxford Biomedica

4.14 Novasep

5.1 Growth Opportunity 1: R&D Investment

5.2 Growth Opportunity 2: Technology Convergence

5.3 Conclusion

6.1 IP Overview in Viral Vector Manufacturing

6.2 Leading Pharmaceutical Patent Holders

6.3 Top Patents in Viral Vector Modifications

6.4 Viral Vector Patents by Spark Therapeutics

6.5 Relevant Viral Vector Patents by University of Pennsylvania

7.1 Representation of Key Participants Based on Revenue

7.2 Key Industry Contacts

7.2 Key Industry Contacts

The rise in gene therapies over the last few years has created a huge opportunity for viral vector Contract Research Development Organization (CMO/CDMO) to fill the gap of high demand and shortage of viral vectors. As of January 2020, the US Food and Drug Administration FDA has approved four gene therapies and claims to have over 900 therapies in the pipeline. This creates a huge demand for viral vectors.
More Information
Deliverable Type Technology Research
No Index No
Podcast No
Author Neeraja Vettekudath
Industries Healthcare
WIP Number D99B-01-00-00-00
Is Prebook No